Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active ph...
Vall d'Hebron Hospital Completes Europe's First Single-Port Robotic Pediatric Nephroureterectomy Using China's Surgerii System
Chinese Drugmaker Huahai Rises After Signing USD340 Million Deal With Spain’s Almirall
The CSI Convertible Bond Index opened down 0.38%. Jiaze Convertible Bonds, Jingda Convertible Bonds, Bester Convertible Bonds, TZTEK Convertible Bonds, and HUAYA INTELLIGENCE Convertible Bonds saw the largest declines, falling 3.04%, 2.99%, 2.97%, 2.74%, and 2.69% respectively. ChangGao NEET Convertible Bonds, Shandong Head Group Convertible Bonds, TRE Convertible Bonds, JINHONG GAS Convertible Bonds, and huahaipharm Convertible Bonds led the gains, rising 30.00%, 10.00%, 3.87%, 3.83%, and 3.56% respectively
National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance
Huahaipharm's subsidiary, Ruixiqi's Bevacizumab Injection marketing authorization application has been accepted
Huahaipharm: Carboxymethyl Sodium Injection has obtained a drug registration certificate